了解冠科生物的最新发表成果。
如果未能找到您想要的信息,请随时联系我们。

Cell-based Platforms to Advance Anti-cancer Drug Discovery

2013

AACR
GLiu-PrimePanel-high throughput in vitro drug screening platform that intimately links in vivo

HLi- Growth of patient derived tumor xenograft PDX in NODSCID mice reconstituted with CD34

QShi-Utilization of in vivo human isogenic cancer models in the new era of targeted therapies

JZhang-Evaluate the efficacy of anti-cancer therapeutics using advanced metastatic mouse models

ADA
Gene expression profiling of Kidneys from NHPs with diabetic nephropathy

ASCO
HLi-Cetuximab response in CRC PDX is predicted by RAS pathway activation rather than KRAS

EORTC

In vivo and in vitro generation and characterisation of EGFR TKI resistance

Tumor growth rate analysis enables cost efficient design of preclinical pharmacology studies

In vivo response and molecular characterization of a Caucasian NSCLC

Metastatic PDX modeling displays correlation between CTC and metastatic potential

Activating EGFR mutation G719A was selected in the c-MET amplified NSCLC-PDX-LU1901

A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy

Squamous non-small cell lung cancer(NSCLC-SCC)patient-derived xenografts (PDX) from Asian patients

2012

ADA
Quantification of glucose-stimulated insulin secretion rate in normal pre-diabetic and diabetic cynomolgus monkeys

2011

ADA
The Expression of KLRD1 is Down-regulated in Insulin Resistant and Type 2 Diabetic Human and Cynomolgus Monkeys